Also authorized vacancies, tres in process and cases 250 more in development. This is the panorama of the vacancies against the covid-19 all over the world.
It’s on the market
Pfizer / BioNTech: Authorized in the European Union, United States, Canada, United Kingdom and many other countries. Developed by the giant Pfizer stadium and the German BioNTech laboratory, it is based on ARN technology and demonstrates a very high efficiency bag (95%).
Modern: another vacancy with ARN messenger, has very similar characteristics to the previous one, with 94.1% efficacy. This vacancy is authorized in the EU, United States, Canada, United Kingdom (where all is not available) and in some other countries, such as Israel in Singapore.
AstraZeneca / Oxford: designed by the English University of Oxford and the AstraZeneca Anglo-Swedish Laboratory, which uses a different technology, called “viral vector”. It is allowed in the UE, in the United Kingdom and in some other less dangerous countries like India (where the number of Covishield is sold), Argentina or Korea of Sur. It is effective at 60% according to the European Medicines Agency (EMA), but it is more difficult and easier to assess than the previous ones. It also has the object of varying degrees of critique, regarding the lack of data relative to its efficacy in major people or their most important secondary effects.
Sputnik V: developed by Russia, this viral vaccine is effective at 91.6%. In addition to Russia, it is homologated in one of the five countries (Belarus, Armenia, Venezuela, Iran, Corea del Sur, Argentina and Argelia, between them). In the UE, if the traumas had been initiated before the EMA, Sputnik V would not have gone to the stage of applying for an authorization.
Sinopharm: the vacancies developed by the Chinese laboratory, which use the classic technique of inactivated virus, are present in China and in many other countries of the world, between the United Arab Emirates, Hungary, Peru, Cambodia and Zimbabwe. According to its designers, there is an efficiency of 79%, but the dates in which they are published are not published.
Sinovac: another Chinese vaccine based on inactivated virus technology, is authorized in China, Chile, Brazil and included in Turkey. Other countries have reserved dose of this vaccine like Ukraine and Uruguay. According to Sinovac, the large-scale trials in Brazil will show a 50% global efficiency rate (and 80% against the most severe forms), but in this case the published dates.
Bharat Biotech: is a vaccine for inactivated viruses in India, authorized in this country.
CanSino: This Chinese viral vaccine was authorized last week in Mexico, but has not yet been administered.
Standing on a truck
Johnson & Johnson: The stadium group has presented applications for authorization in the European Union and in the United States for this viral vector vaccine manufactured by its subsidiary Janssen Cilag. It is effective at 66% and generally 85% against graft forms, according to the manufacturer. The difference between the two, only requires an injection and no dose.
Novavax: The EMA is examining this vacancies, which will allow the truck to apply for a UE authorization. It is a vaccine based on proteins that cause an immune response, without viruses. Its designers claim that it is effective at 89.3%.
CureVac: This German vacancy also entered the quarters during the EMA’s continuous examination procedure. It was taken from an ARN message box.
The vacancies at the station
According to the World Health Organization, there are 69 vacancies against covid-19 as the object of clinical trials in human beings. In addition to 181 vacancies that are in the preclinical development phase and have not yet been tested on humans.